Journal: bioRxiv
Article Title: PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer
doi: 10.1101/2022.06.27.497846
Figure Lengend Snippet: (A) Kaplan-Meier survival analysis of mice injected with either ID8- Trp53 -/- , ID8- Trp53 -/- ; Pten -/- and ID8- Trp53 -/- ; Brca1 -/- cells. (n = 10-15) for each treatment group. (B) In vivo bioluminescent imaging of mice injected with ID8- Trp53 -/- ; Pten -/- and ID8- Trp53 -/- ; Brca1 -/- luciferase-tagged cells tracking tumor progression once/week over 4 weeks. Total RNA from untreated tumors of different genotypes was subject to NanoString gene expression profiling using the panCancer immune gene panel displayed as a (C) heat map showing differential expression pattern of groups of genes involved in various immune functions, (D) 2-fold differentially expressed genes and (E) 0.5-fold differentially expressed genes. Proportion of cells derived from ascites of mice injected with ID8- Trp53 -/- ; Pten -/- and ID8- Trp53 -/- ; Brca1 -/- cells expressing (F) CD45+CD3+CD8+CD69+, (G) CD45+CD11b+F4/80+CD206+, and (H) CD45+CD11b+GR1+. (I) IL-6, (K) IL-10 and (G) CXCL-10 cytokine levels derived from the ascites fluid of untreated mice injected with ID8- Trp53 -/- ; Pten -/- and ID8- Trp53 -/- ; Brca1 -/- cells. Log-rank (Mantel-Cox) test was applied to derive significant differences in (A). Mann-Whitney non-parametric test was used for (F-L) * p<0.05, ** p<0.005, *** p<0.001, **** p<0.0001. Gene expression data analysis was performed using nSolver Advanced Analysis Software. Mean ± SD.
Article Snippet: Splenic T cells were enriched using a magnetic-based commercial CD8 T cell negative selection kit (StemCell Technologies, BC, Canada; ) as per the manufacturer’s protocol.
Techniques: Injection, In Vivo, Imaging, Luciferase, Expressing, Derivative Assay, MANN-WHITNEY, Software